Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00276913 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Synta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00276913: Completed Phase 1 study, sponsored by Synta Pharmaceuticals.
NCT00276913 is a Phase 1 study that has completed, run by Synta Pharmaceuticals. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00276913, a Phase 1 study, has completed, sponsored by Synta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Primary Objectives: * To determine the safety, toxicity and the maximum tolerated dose (MTD) of intravenous STA-5312 when administered weekly (3 of 4 weeks) to subjects with advanced or metastatic solid tumors. * To determine the pharmacokinetics of STA-5312. Secondary Objective: • To assess antitumor activity of STA-5312 administration.
Interventions
- DRUG STA-5312
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00276913
The ClinicalTrials.gov registry entry for NCT00276913 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synta Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STA-5312 is the first listed.
NCT00276913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00276913 about?
NCT00276913 is a clinical study titled "A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors". Primary Objectives: * To determine the safety, toxicity and the maximum tolerated dose (MTD) of intravenous STA-5312 when administered weekly (3 of 4 weeks) to subjects with advanced or metastatic solid tumors. * To determine the pharmacokinetics of STA-5312. Secondary Objective: • To assess anti...
What is the current status of trial NCT00276913?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2004-06.
What interventions are being tested in trial NCT00276913?
The interventions under investigation include: STA-5312 (DRUG).
Who is sponsoring clinical trial NCT00276913?
This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.